#44: Obesity Medication Overview from AACE 2017
Master the safe and effective use of obesity medications with Endocrinologist, Dr. Karl Nadolsky (co-author of 2016 AACE Obesity guidelines), Director of the Diabetes, Obesity & Metabolic Institute at Walter Reed National Military Medical Center. We get under the hood of each FDA approved obesity medication plus some of our normal hijinks. Check out episode #23 for a more general overview of obesity.
Full show notes available at http://thecurbsiders.com/podcast
Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.
Time Stamps
00:00 Intro
03:12 Picks of the week
08:44 Rapid fire questions
13:00 Counsel patients about obesity
14:40 Pathophysiology of obesity
18:00 Case
22:46 Phentermine/topiramate (Qsymia)
26:20 Bupropion/naltrexone (Contrave)
29:18 Liraglutide (Saxenda)
34:32 Orlistat (Alli, Xenical)
37:35 Cost issues
40:18 Lifelong medical therapy for obesity
42:44 Dr. Nadolsky’s take home points
44:45 The Curbsiders recap and discuss their experience with obesity medications
52:28 Outro
Tags: assistant, care, doctor, education family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, physician, practitioner, primary, resident, student, obesity, pharmacotherapy, weight loss, safety, side effects, orlistat, alli, naltrexone, bupropion, contrave, phentermine, topiramate, qsymia, lorcaserin, belviq, FDA